NASDAQ:LEXX

Lexaria Bioscience (LEXX) Stock Forecast, Price & News

$0.74

-0.03 (-3.88%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.74
▼
$0.77
50-Day Range: $0.69
▼
$2.69
52-Week Range: $0.65
▼
$3.60

Volume: 70,552 shs
Average Volume: 291,529 shs
Market Capitalization: $4.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Lexaria Bioscience MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.07) to ($0.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lexaria Bioscience.

5.0

Short Interest

Percentage of Shares Shorted
3.59% of the float of Lexaria Bioscience has been sold short.
Short Interest Ratio / Days to Cover
Lexaria Bioscience has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lexaria Bioscience has recently decreased by 14.38%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Lexaria Bioscience does not currently pay a dividend.
Dividend Growth
Lexaria Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LEXX.

2.1

News and Social Media Coverage

News Sentiment
Lexaria Bioscience has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.58% of the stock of Lexaria Bioscience is held by insiders.
Percentage Held by Institutions
Only 11.56% of the stock of Lexaria Bioscience is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lexaria Bioscience are expected to grow in the coming year, from ($1.07) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lexaria Bioscience is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lexaria Bioscience is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lexaria Bioscience has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lexaria Bioscience (NASDAQ:LEXX) Stock

Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.

Receive LEXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

LEXX Stock News Headlines

June 6, 2023 | americanbankingnews.com

Contrasting Lexaria Bioscience (NASDAQ:LEXX) & Revelation Biosciences (NASDAQ:REVB)

May 29, 2023 | americanbankingnews.com

Lexaria Bioscience Corp. (NASDAQ:LEXX) Short Interest Down 14.4% in May

June 10, 2023 | Vector Vest (Ad)

Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 24, 2023 | theglobeandmail.com

Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Study

May 23, 2023 | msn.com

Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases

May 18, 2023 | finance.yahoo.com

Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH

May 18, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

May 18, 2023 | finance.yahoo.com

Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

June 10, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: See The True Value of Any Stock

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 12, 2023 | marketwatch.com

CannabisNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial

May 11, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Lexaria Bioscience Announces Closing of $2.0 Million Public Offering

May 11, 2023 | finance.yahoo.com

Lexaria Bioscience Announces Closing of $2.0 Million Public Offering

May 11, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

May 11, 2023 | finance.yahoo.com

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

May 8, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering

May 8, 2023 | finance.yahoo.com

Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering

April 25, 2023 | americanbankingnews.com

Analysts Set Expectations for Lexaria Bioscience Corp.'s Q3 2023 Earnings (NASDAQ:LEXX)

April 24, 2023 | finance.yahoo.com

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study

April 21, 2023 | marketwatch.com

TinyGemsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents

April 20, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Lexaria is Receiving Four New Patents

April 20, 2023 | finance.yahoo.com

Lexaria is Receiving Four New Patents

April 5, 2023 | theglobeandmail.com

Lexaria (NASDAQ: LEXX) Targeting Multiple Applications for DehydraTECH(TM) Platform

April 2, 2023 | americanbankingnews.com

Lexaria Bioscience (NASDAQ:LEXX) Stock Price Up 0.9%

March 7, 2023 | finance.yahoo.com

Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?

March 2, 2023 | finance.yahoo.com

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels

February 23, 2023 | finanznachrichten.de

Lexaria Bioscience Corp.: Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

February 21, 2023 | finance.yahoo.com

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

See More Headlines

LEXX Price History

30 days | 90 days | 365 days | Advanced Chart

LEXX Company Calendar

Last Earnings: 4/14/2023
Today: 6/10/2023
Next Earnings (Estimated): 7/13/2023
Fiscal Year End: 8/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LEXX
CUSIP: N/A
CIK: 1348362
Web: www.lexariabioscience.com
Phone: (250) 765-6424
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,270,000.00
Net Margins: -1,984.20%
Pretax Margin: -2,014.94%
Return on Equity: -101.87%
Return on Assets: -98.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.95
Quick Ratio: 17.92

Sales & Book Value

Annual Sales: $347,358.00
Price / Sales: 12.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.28 per share
Price / Book: 0.58

Miscellaneous

Outstanding Shares: 5,986,000
Free Float: 5,413,000
Market Cap: $4.45 million
Optionable: Not Optionable
Beta: 0.63

Key Executives

Mr. Christopher A. Bunka (Age 61)
Chairman & CEO
Comp: $253.11k

Mr. John M. Docherty M.Sc. (Age 54)
Pres & Director
Comp: $220.23k

Mr. Gregory John Downey CMA (Age 62)
CPA, CFO & Treasurer
Comp: $94.14k

Kristin Hamilton
Director of Operations

Vanessa Carle
Head of Legal

Dr. Philip N. Ainslie Ph.D.
Advisor & Consultant

Key Competitors

View All Competitors

Insiders

Catherine C Turkel
Bought 1,500 shares on 2/9/2023
Total: $4,260.00 ($2.84/share)

View All Insider Transactions

LEXX Stock - Frequently Asked Questions

How have LEXX shares performed in 2023?: Lexaria Bioscience's stock was trading at $2.46 on January 1st, 2023. Since then, LEXX shares have decreased by 69.8% and is now trading at $0.7434.
View the best growth stocks for 2023 here.
When is Lexaria Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 13th 2023.
View our LEXX earnings forecast.
How were Lexaria Bioscience's earnings last quarter?: Lexaria Bioscience Corp. (NASDAQ:LEXX) posted its quarterly earnings data on Friday, April, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million for the quarter. Lexaria Bioscience had a negative trailing twelve-month return on equity of 101.87% and a negative net margin of 1,984.20%.
What is Lexaria Bioscience's stock symbol?: Lexaria Bioscience trades on the NASDAQ under the ticker symbol "LEXX."

How do I buy shares of Lexaria Bioscience?: Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lexaria Bioscience's stock price today?: One share of LEXX stock can currently be purchased for approximately $0.74.
How much money does Lexaria Bioscience make?: Lexaria Bioscience (NASDAQ:LEXX) has a market capitalization of $4.45 million and generates $347,358.00 in revenue each year. The company earns $-7,270,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis.
How can I contact Lexaria Bioscience?: Lexaria Bioscience's mailing address is 100 - 740 MCCURDY ROAD, KELOWNA A1, V1X 2P7. The official website for the company is www.lexariabioscience.com. The company can be reached via phone at (250) 765-6424 or via email at info@lexariabioscience.com.

This page (NASDAQ:LEXX) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial